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Abstract 9 
Background: Biological medicines are starting to lose their patent protection, so similar, 10 
inexact copies (biosimilars) are being developed and licensed. The high acquisition costs of 11 
biologics for healthcare providers could be reduced by switching to biosimilars, thus alleviating 12 
budgetary pressures and increasing patient access. Therefore, the acceptance of biosimilars by 13 
prescribers in Great Britain (GB; England, Scotland, Wales) needs to be described and 14 
understood. 15 
Objective: To determine uptake of the first wave of biosimilars (somatropin, epoetin, 16 
filgrastim) by local formularies (lists of preferred medicines for prescribing in local healthcare 17 
settings). 18 
Settings: This study targeted local formularies in GB. 19 
Method: In November 2014, local formularies (medicines formularies of Acute Trusts and 20 
Health Boards in GB) were screened for their approach to listing of biologics and their 21 
biosimilars as well as recommendations on usage of these pharmaceuticals.  22 
Main Outcomes Measures: Listing frequencies of biosimilars.  23 
Results: One hundred and forty-six British local formularies were screened. Amongst the 80% 24 
of formularies in which brand names were specified, biosimilar filgrastim was the most 25 
frequently listed when compared to the other targeted biosimilars. Biosimilars were listed in 26 
preference to reference biologic medicine in 49% of local formularies for filgrastim, 11% for 27 
somatropin and in only 6% for epoetin. 28 
Conclusion: Although the market for biosimilars can act in parallel to the generic market, their 29 
uptake measured using local British formularies was less than what is expected given that the 30 
British market for medicines has a strong focus on generics. Finally, geographical variability 31 
within GB requires further investigation. 32 
  33 
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Impacts of findings 34 
 As the use of brand names in prescribing and reporting adverse drug reactions is part 35 
of active monitoring of biological medicines safety, including the biosimilar medicines, 36 
local formularies must actively list these medicines using brand name; 37 
 Specifying preferred brand for prescribing facilitates and promotes local formularies in 38 
guiding cost effective and rational medicines utilisation.  39 
 40 
 41 
  42 
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Introduction  43 
Biological medicines (BMPs) provide an innovative method for treating chronic and life-44 
threatening diseases such as cancers, rheumatoid arthritis and multiple sclerosis. Their rapid 45 
adoption into clinical practice has resulted in a substantial share of the pharmaceutical market; 46 
for example, in 2012-2013, 27% of total pharmaceutical sales in Europe were BMPs [1]. 47 
Moreover, eight of the top ten bestselling pharmaceuticals in 2013 in Europe were BMPs. It is 48 
expected that BMPs will maintain the same market share into 2016 [2,3] and likely beyond. 49 
BMPs have significantly improved health and disease outcomes, but their widespread 50 
utilisation is financially challenging to healthcare providers worldwide [4]. 51 
In 2013-2014, in England, seven out of the top ten most prescribed medicines in terms of cost 52 
to the National Health Service (NHS) were BMPs [5]. Notable though is that all seven will lose 53 
their patent protection by 2018 [6]. Patent expiry creates an opportunity for developing and 54 
licensing similar copies of off-patent BMPs-called biosimilar medicines (BSPs) [7]. Unlike 55 
conventional generic medicines, BSPs are not identical but similar copies of their reference 56 
BMP (R-BMP). The inability to produce identical copies is related to the complex and 57 
heterogenic molecular structure of these medicines, and being produced by not fully 58 
controllable living systems [4,8]. 59 
In their analysis of the European BSP market, Rovira et al reported that BSPs offer price 60 
reductions of between 10% and 35% [9]. Although this is a modest price reduction in 61 
comparison to conventional generic medicines, the overall cost saving to health service 62 
providers is expected to be significant due to the high unit costs and extensive use of BMPs 63 
[9]. The European Generic Medicines Association reported that the European Union might 64 
save upwards of €1.6 billion/year for the scenario in which a 20% price reduction occurs on 65 
five off-patent BMPs [10]. Furthermore, it has been suggested that the availability of BSPs 66 
might alter medical practice and increase compliance to clinical guidelines [11,12]. 67 
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In Europe, BSPs can be launched after being centrally assessed and licensed by the European 68 
Medicines Agency (EMA) for safety, quality and efficacy [8,11]. While the EMA mandates 69 
full quality submission in order to license a BSP, it does permit evidence based extrapolation 70 
of the clinical outcomes from one tested indication to closely related others [13,14].  71 
In Great Britain (GB), the Medicines and Healthcare products Regulatory Agency (MHRA) 72 
directs prescribers to use brand name in prescribing any BMP and its BSPs [15]. Brand name-73 
based prescribing and reporting facilitates capture of safety issues related to BMPs including 74 
BSPs [15].  75 
Despite being a generically-driven market [16], the uptake of BSPs in Britain seems to have 76 
been relatively limited when compared to other European countries [14]. According to the 77 
British Generic Manufacturers Association factors related to physicians’ lack of confidence in 78 
prescribing BSPs, absence of encouraging national policies and banned substitution at 79 
pharmacy level have resulted in slow adoption of BSPs [14]. Lack of confidence might relate 80 
to physicians questioning the safety and efficacy of BSPs [11]. This might be at least partly 81 
explained by the abridged approach the EMA follows in assessing clinical efficacy of BSPs 82 
[13]. One exception is granulocyte-colony stimulating factor (G-CSF)-filgrastim BSP, which 83 
is achieving an uptake rate similar to that of conventional generic medicinal products [2].  84 
One approach to evaluating prescribers’ acceptance of BSPs is through assessing uptake of 85 
BSPs in local medicines formularies. The National Institute for Health and Care Excellence 86 
(NICE) defines local formularies as “the output processes to support the managed introduction, 87 
utilisation or withdrawal of healthcare treatments within a health economy, service or 88 
organisation” [17]. Local formularies are working documents that are subject to regular review 89 
and change. They tend to be robust on treatments used frequently and weak on occasionally 90 
used ones (that need to be available for a complete and comprehensive service). Local 91 
formularies can act as prescribing guiding tool at local settings [18]. Heal et al (2004) reported 92 
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that more than 80% of their study participants were guided by local formularies [19]. 93 
Accordingly, assessing BSP listing in local formularies might reflect acceptance of these 94 
products by prescribers.  95 
Aim of the study 96 
To determine uptake acceptance of first wave BSPs licensed and marketed in GB prior to 2015 97 
(somatropin (HGH), epoetin (EPO) and filgrastim (G-CSF)) by local formularies. 98 
Ethics approval 99 
Ethical approval was not needed as local formularies throughout the UK are publically 100 
available documents included in the freedom of information scheme. 101 
Method 102 
During November-December 2014, a list of 1571 Acute Trusts (accountable organisations 103 
within NHS England that manage and control the performance, services quality and financial 104 
efficiency of clusters of hospitals in England) was acquired from the NHS England website. 105 
Details of the 14 Regional Health Boards in Scotland and 7 Local Health Boards in Wales 106 
(accountable organisations within NHS Scotland and NHS Wales that are responsible for the 107 
delivery of healthcare services to the local population) were acquired from Scottish 108 
Government and NHS Wales websites2.  109 
                                           
1 As of November 2014, the total number of Acute Trusts in England was 157. It was not possible to obtain the 
formulary list of two Acute Trusts since one was dissolved and the other one was still in process of developing a 
formulary list. 
2 Northern Ireland was excluded as there was an initiative underway to develop a joint formulary for the whole 
country, and some of its chapters were still under development. 
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The most recent versions of local medicines formularies were downloaded and examined for 110 
their listing of targeted R-BMPs and BSPs according to the criteria given in Table 1. These 111 
criteria enabled assessment of: (i) uptake of BSPs, (ii) compliance to the MHRA 112 
recommendation on brand name prescribing of BMPs, and (iii) the consideration given to 113 
population or indication-specific recommendations.  114 
The assessment process started by examining whether the listing approach of R-BMP and BSPs 115 
was based on using brand name, molecular name or both, as per the British National Formulary 116 
(BNF) 68th edition. Then the availability of prescribing guidance in terms of speciality of the 117 
prescriber and/or the clinical settings was recorded. Finally, formulary entries were classified 118 
and compared according to preferred brand for prescribing. Formulary uptake of targeted 119 
BMPs and BSPs was analysed using descriptive statistics in an Excel® 2010 spreadsheet.  120 
 121 
Results  122 
One hundred and forty-six formularies were identified: 129 in England, 10 in Scotland and 7 123 
in Wales. Forty-three percent (63/146) of these were joint formularies (the term given to a local 124 
formulary developed and/or used simultaneously by more than one healthcare providing 125 
organisation).  126 
Formulary uptake and listing approaches varied across the three targeted groups. HGH was 127 
listed in 126 formularies achieving the highest percentage of medicine listing, EPO achieved 128 
the highest brand name based listing with 60 formularies using brand names. Despite BSP G-129 
CSF being the last of the three groups to be authorised by the EMA, it was most commonly 130 
listed in preference to the R-BMP. Table 2 provides more details.  131 
Variations between the countries of GB were seen, with 27% of English formularies listing 132 
BSP G-CSF in preference to the R-BMP, versus 12.5% and 14.3% amongst Scottish and Welsh 133 
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formularies, respectively. In the cases of HGH and EPO, 6% and 4% of English formularies 134 
preferred BSP over R-BMP; respectively, but no Scottish or Welsh formularies did so. 135 
Only six formularies listed at least one BSP from all three targeted groups. There were no 136 
instances of BSPs being preferred to R-BMPs across all three targeted groups, but at the 137 
opposite extreme there were only two formularies in which R-BMPs were always preferred 138 
over BSPs. 139 
Discussion 140 
In this study, formulary uptake of BSPs in three different groups was employed as an indicator 141 
of clinical acceptance of BSPs in GB. The uptake of BSPs by British local formularies was less 142 
than what might be predicted from a classical generically driven market for medicines, and 143 
there appeared to be geographic variability in uptake which requires further investigation. 144 
Most frequently listed was HGH, the first licensed BSP [20], however the maximum preference 145 
for BSPs over R-BMP was achieved by G-CSF BSPs. On the other hand, brand name-based 146 
listing was more frequent in the case of EPO. Despite it not being possible to gain a complete 147 
understanding of the variations between targeted groups, it might be explained in large part by 148 
the molecular nature, therapy duration and/or patients’ demographics, preferences and life 149 
style. 150 
Having several other medicinal products within the same group where each has different dosing 151 
frequencies, administration devices and storage conditions might affect acceptance of BSPs. 152 
For example, one HGH product is a needleless device making it more attractive to paediatric 153 
and needle-phobic patients. Another HGH product can be stored out of the refrigerator [21] 154 
which might make it the brand of choice for frequent travellers. 155 
G-CSF’s molecular structure and short duration of therapy might increase the acceptance of its 156 
BSPs. It is a small, easily characterised non-glycosylated molecule that is indicated for short 157 
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therapeutic periods [22, 23]. However, special population considerations in terms of patient 158 
age and therapeutic indications were flagged in those instances when the R-BMP was listed in 159 
preference to BSPs. Specifically, the R-BMP was listed as the preferred product for paediatric 160 
patients and for stem cell mobilisation. Reluctance to use BSPs in these settings may be because 161 
of the lack of clinical trial evidence of their efficacy and/or safety. 162 
EPO achieved the highest percentage of brand name-based listing. This is most likely due to 163 
EPO being a glycosylated protein, in which case each brand has a different glycosylation 164 
pattern and hence a different immunogenic profile [24]. In addition, previously reported cases 165 
of the life threatening pure red cell aplasia might encourage the use of brand name based listing 166 
for EPO whether for the R-BMP or the BSPs [24]. 167 
The MHRA has considered several measures in the monitoring of BMPs, including BSPs, such 168 
as: demanding brand name-based prescription, and requiring specification of a product’s 169 
identifiers (brand name, batch number and manufacturer) in reporting adverse drug reactions. 170 
Furthermore, prescribers are directed to inform patients and/or carers about a product’s brand 171 
name and batch number [15]. However, more than one third of local formularies did not specify 172 
brand names when listing BMPs in the groups examined in this study. Unintentional switching 173 
between brands might affect patients’ safety, if not carefully monitored and managed. Such 174 
harm might be avoided in the cases of G-CSF and EPO because of their short duration 175 
prescription, but possibly not otherwise for HGH which is typically used for prolonged periods.  176 
The limited clinical evidence of BSPs’ efficacy has been highlighted as a factor hindering 177 
BSPs’ acceptance in clinical practice [22]. However, the BSP G-CSF brand that was approved 178 
based on results of a pharmacokinetics/pharmacodynamics trial in healthy volunteers instead 179 
of patients, and in a non-comparative safety-focussed study in patients [25] -was recommended 180 
for use ahead of R-BMP G-CSF in more local formularies than was any other 181 
biosimilar/reference pairing. 182 
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As there is a proposal to assign different international non-proprietary name (INN) for BSPs, 183 
BSPs' manufacturers argue that a differing INN might limit the uptake of BSPs by giving 184 
suggestion to the view that BSPs are completely different instead of being a highly similar 185 
molecule [26]. The effect of different INN was noted in the case of epoetin zeta and epoetin 186 
alfa, where despite both being EPO BSP the latter was more often listed than the former. 187 
Moreover, 50% of formularies that preferred BSP EPO over the R-BMP have not listed epoetin 188 
zeta, while the remaining 50% listed it without brand specification. Of the 27 formularies that 189 
did list EPO using its molecular name none included epoetin zeta. 190 
Variations in listing BSPs were observed between England, Scotland and Wales. Although 191 
both the Scottish Medicines Consortium and the All Wales Medicines Strategy Group have 192 
been actively involved in evaluating BSPs [27, 28], Scottish and Welsh formularies were less 193 
likely to list BSPs in preference to the R-BMP compared with their English counterparts.  194 
Research data and analysis indicate that some formularies encourage BSP prescribing. 195 
However, variations and lack of specificity in some formularies may suggest a vague 196 
understanding of the concept and nature of BMPs in general, and BSPs in particular, by the 197 
professionals involved in developing local formularies. 198 
The principal limitation of this study is that the uptake of BSPs has been estimated using local 199 
medicines formularies as a proxy for actual prescribing practice. This may not necessarily 200 
provide a highly accurate reflection of BSP prescribing, as it is not known to what degree these 201 
lists are adhered to.  202 
If equally safe and effective as the originator BMP, lower prices for BSPs could potentially 203 
increase access to treatment for more patients, or reduce drug spending in an increasingly 204 
constrained financial environment. Engagement is required with prescribers, formulary 205 
managers and commissioners to understand the basis for formulary decision-making, identify 206 
reasons for variation in prescribing behaviour and develop strategies for more uniform uptake 207 
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of BSPs. Educational interventions are also needed around adherence to standards of 208 
pharmacovigilance to assure drug monitoring and patient safety. 209 
 210 
Conclusion 211 
The results of this study suggest that the uptake of BSPs in Britain is highly variable, and 212 
generally less than what is expected, given historically that its market for pharmaceuticals is 213 
very much generically driven. Further work is needed to understand why there is such low and 214 
variable uptake.  215 
 216 
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Table 1 
 
Table 1- Formulary assessment criteria 
No.  Assessment Criterion    Definition 
1. Is this formulary a joint formulary? (Yes/No)   
Formulary list that is developed and/or used by more than one healthcare setting (primary and/or secondary 
care). 
 
2. 
   BNF chapter 6.5.1*: somatropin (HGH) 
Is the targeted medicine listed? (Yes/No)   BNF chapter 9.1.3**: epoetin alfa (EPO) 
   BNF chapter 9.1.6***: filgrastim (G-CSF) 
 
 
    Formulary Medicinal product that is routinely available for prescription.  
3. How it is listed? (formulary/non-formulary)   
    Non-formulary 
Medicinal product that is not routinely available for prescription.  
However, if it is deemed needed, it will be made available for the patient. 
 
 
4. What is the listing approach? (Brand name/INN/Both)   As per brands listed in BNF chapters 6.5.1, 9.1.3 and 9.1.6. 
 
 
5. 
   BNF chapter 6.5.1: 1 R-BMP and 1 BSP 
What are the listed brands? (R-BMP/BSP/Both)   BNF chapter 9.1.3: 1 R-BMP and 2 BSPs 
   BNF chapter 9.1.6: 1 R-BMP and 3 BSPs 
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6. 
   
Being the only listed brand/type; 
Clearly stated that this brand/type is the preferred for prescription; or 
Brand/type listed as formulary while other brands/type listed as non-formulary. 
What is the preferred type?  
(R-BMP/BSP/Not specified) 
  
   
 
 
7. Are there clear restrictions in prescribing? (Yes/No)   
Whether or not there are specified restrictions in terms of who can prescribe these products and/or 
prescribing settings i.e. primary or secondary care. 
 
8.  Is there specified brand of choice? (Yes/No)   If it is clearly stated that a specific brand is considered as the brand of choice. 
 
 
9.  Are there special population considerations? (Yes/No)   
If there are considerations related to patients’ age, medical history and/or life style factors that might affect 
type/brand of preference (R-BMP or BSP). 
 
10.  Are there special indications’ considerations? (Yes/No)   If there are considerations related to indications that might affect type/brand of preference (R-BMP or BSP). 
BNF: British National Formulary 68th Edition; BMP: Biological medicinal product; BSP: Biosimilar medicinal product; INN: International non-proprietary name(molecular name); 
R-BMP: Reference biological medicinal product  
*6.5.1: Drugs used in hypothalamic and anterior pituitary hormones and anti-oestrogen; 1 R-BMP and 1 BSP brand  
**9.1.3: Drugs used in hypoplastic, haemolytic, and renal anaemias; 1 R-BMP and 2 BSP brands 
***9.1.6: Drugs used in neutropenia; 1 R-BMP and 3 BSP brands 
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Table 2 
Table 2- Results Summary  
Investigated Attributes  
Medicine Group 
Filgrastim  
(G-CSF) 
Epoetin alfa 
(EPO) 
Somatropin 
(HGH) 
Medicine being listed   
 Not listed  27 (18%)  31 (21%)  20 (14%)  
 Listed as Formulary  115 (79%)  107 (73%)  120 (82%)  
 Listed as Non-formulary 4 (3%) 8 (6%)  6 (4%)  
 Total 146 146 146 
 
Clear Prescription Restrictions 
 Yes 78 (66%) 77 (67%) 84 (67%) 
 No 41 (34%) 38 (33%) 42 (33%) 
 Total 119 115 126 
 
Listing approach  
 INN name 58 (49%) 44 (38%) 64 (51%) 
 Brand names 49 (41%) 60 (52%) 59 (47%) 
 Mixed Listing 12 (10%) 11 (10%) 3 (2%) 
 Total 119 115 126 
 
Listed Brands  
 Both 36 (59%) 21 (30%) 25 (40%) 
 R-BMP Only 11 (18%) 48 (68%) 4 (7%) 
 BSPs Only 14 (23%) 2 (3%) 33 (53%) 
 Total 61 71 62 
 
Preferred Type   
 R-BMP 10 (16%) 52 (73%) 29 (47%) 
 BSPs 30 (49%) 4 (6%) 7 (11%) 
 Unclear  21 (34%) 15 (21%) 26 (42%) 
 Total 61 71 62 
 
Specified Brand of Choice  
 Yes 13 (21%) 4 (6%) 9 (15%) 
 No 48 (79%) 67 (94%) 53 (85%) 
 Total 61 71 62 
 
Special Population Considerations3  
 Yes 3 (5%) 8 (11%) 10 (16%) 
 No 58 (95%) 63 (89%) 52 (84%) 
 Total 61 71 62 
 
Special Indication Considerations    
 Yes 9 (15%) 7 (10%) 0 (0%) 
 No 52 (85%) 64 (90%) 62 (100%) 
 Total 61 71 62 
 
BSP: Biosimilar medicinal product; INN: International non-proprietary name (molecular name); R-BMP: 
Reference biological medicinal product   
 
 
                                           
3 Factors related to patient population or indication that might affect prescriber brand/product of choice.  
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